NasdaqGS:GHHealthcare
Could Guardant Health's (GH) Expansive ESMO 2025 Data Redefine Its Long-Term Innovation Edge?
Guardant Health announced that it recently presented new data from 15 oncology studies spanning multiple cancer types at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin.
Key highlights included novel applications for tumor profiling and minimal residual disease detection, offering insights into early cancer recurrence monitoring and addressing critical gaps in cancer diagnosis.
We'll explore how the breadth of new clinical data presented at ESMO 2025 could influence...